Last $2.51 USD
Change Today -0.08 / -3.09%
Volume 26.8K
PDII On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

pdi inc (PDII) Snapshot

Open
$2.48
Previous Close
$2.59
Day High
$2.61
Day Low
$2.45
52 Week High
01/6/14 - $6.25
52 Week Low
09/17/14 - $2.45
Market Cap
38.6M
Average Volume 10 Days
18.9K
EPS TTM
$-0.67
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PDI INC (PDII)

pdi inc (PDII) Related Bloomberg News

View More Bloomberg News

pdi inc (PDII) Related Businessweek News

No Related Businessweek News Found

pdi inc (PDII) Details

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, and healthcare companies in the United States. The company’s services offer customers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It operates in three segments: Sales Services, Marketing Services, and Product Commercialization Services. The Sales Services segment focuses primarily on product detailing, which includes a sales representative meeting face-to-face with targeted physicians and other healthcare decision makers to provide a technical review of the product being promoted and deliver marketing materials, including samples. It also offers a portfolio of sales services consisting of talent acquisition services, short-term teams, and vacancy coverage services. The Marketing Services segment is involved in the creation, design, and implementation of interactive digital communications programs to the healthcare community through the Internet, multimedia, tablet PCs, mobile devices, and dimensional direct mails, as well as DIAGRAM, a proprietary software to deliver digital selling solutions through interactive communications exchanges that accommodate the schedules of healthcare providers. This segment is also engaged in the creation of teledetailing programs executed through tele-representatives. The Product Commercialization Services segment provides product commercialization solutions, including product distribution, product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management to pharmaceutical, biotechnology, medical device, and diagnostics clients. PDI, Inc. has a strategic collaboration agreement with Transgenomic, Inc. The company was founded in 1987 and is headquartered in Parsippany, New Jersey.

706 Employees
Last Reported Date: 03/6/14
Founded in 1987

pdi inc (PDII) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $539.4K
President of Sales Services
Total Annual Compensation: $488.5K
Compensation as of Fiscal Year 2013.

pdi inc (PDII) Key Developments

Heiner Dreismann Joins PDI, Inc.'s Board of Directors

PDI reported that Heiner Dreismann, Ph.D., former president and chief executive officer of Roche Molecular Systems, has joined its board of directors. The company said that his addition, effective immediately, brings the total number of board members to seven. Dr. Dreismann possesses more than 27 years of global diagnostics experience in various positions at Roche Diagnostics and later Roche Molecular Systems (RMS).

PDI, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Full Year 2014

PDI, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue, net of $31,578,000 against $37,245,000 a year ago. Operating loss was $2,523,000 against $847,000 a year ago. Loss from continuing operations before income tax was $2,536,000 against $871,000 a year ago. Loss from continuing operations was $2,601,000 or $0.17 per basic and diluted share against $935,000 or $0.06 per basic and diluted share a year ago. Net loss was $2,658,000 or $0.18 per basic and diluted share against $883,000 or $0.06 per basic and diluted share a year ago. Adjusted LBITDA was $1,475,000 compared to adjusted EBITDA of $164,000 a year ago. Revenue for the second quarter of 2014 was 15% lower than the second quarter of 2013 driven by the natural expiration or reduction of contracts being executed in 2014 exceeding new contracts entered into in the company's Sales Services segment. The 2014 operating loss was primarily the result of the anticipated lower revenue and margins as well as the company's investment in strategic initiatives. The company's adjusted EBITDA loss of $1.5 million in the quarter was primarily driven by spending on key strategic initiatives and lower gross profit. For the six months, the company reported revenue, net of $64,356,000 against $80,168,000 a year ago. Operating loss was $4,020,000 against operating income of $1,406,000 a year ago. Loss from continuing operations before income tax was $4,050,000 against income from continuing operations before income tax of $1,372,000 a year ago. Loss from continuing operations was $4,181,000 or $0.28 per basic and diluted share against income from continuing operations of $1,244,000 or $0.08 per basic and diluted share a year ago. Net loss was $4,270,000 or $0.29 per basic and diluted share against net income of $1,242,000 or $0.08 per basic and diluted share a year ago. Net cash used in operations was $8,288,000 against $574,000 a year ago. Adjusted LBITDA was $1,825,000 compared to adjusted EBITDA of $3,056,000 a year ago. As for the company's outlook for the remainder of 2014, the company continues to expect revenue in core business to be down in the third quarter and for the full year compared to 2013. The company still anticipates an operating loss in the range of $4 - $5 million and approximately breakeven adjusted EBITDA in the core business for the full year 2014. The company see a modest amount of revenues from Interpace Diagnostic for 2014 and an operating loss in the range of $5 - $6 million from all Interpace Diagnostics activities including additional selling and marketing and pre-launch expenses to support the anticipated ramp up of revenue from the acquired Asuragen assets.

Heiner Dreismann Joins PDI Inc.'s Board of Directors

PDI, Inc. announced that Heiner Dreismann, Ph.D., former president and chief executive officer of Roche Molecular Systems, Inc., has joined its board of directors. Effective immediately, his addition brings the total number of board members to seven. Dr. Dreismann also serves on the boards of directors of several other public and privately held companies, including GeneNews, Stratos Genomics, Magellan Diagnostics, Singulex, Celula, Inc. and Myriad Genetics, among others.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDII:US $2.51 USD -0.08

PDII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDII.
View Industry Companies
 

Industry Analysis

PDII

Industry Average

Valuation PDII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDI INC, please visit www.pdi-inc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.